Modulating antibody pharmacokinetics using hydrophilic polymers

Expert Opinion on Drug Delivery

Volumn 8, Issue 9, 2011, Pages 1221-1236

  Chen, Chen ^a   Constantinou, Antony ^a   Deonarain, Mahendra ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Fragment; Hydrodynamic; Pharmacokinetics; Polyethylene glycol; Polysialic acid

Indexed keywords

ALACIZUMAB PEGOL; ANTIBODY; BEVACIZUMAB; CARBOPLATIN; CDP 7657; CDP 7675; CDP 860; CERTOLIZUMAB PEGOL; DEXTRAN; DX 1000; HETASTARCH; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PACLITAXEL; PEGADEMASE; PEGAPTANIB; PEGDINETANIB; PEGINTERFERON ALPHA2A; POLYACRYLAMIDE; POLYGLUTAMIC ACID; POLYMER; POLYPEPTIDE; PRS 050; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; XTEN;

AREA UNDER THE CURVE; CHEMICAL ENGINEERING; CHEMICAL MODIFICATION; CONFORMATION; CONJUGATE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG HALF LIFE; DRUG STABILITY; HUMAN; HYDRODYNAMICS; HYDROGEN BOND; HYDROPHILICITY; IMMUNOGENICITY; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; NONHUMAN; REVIEW; RHABDOMYOSARCOMA; SIALYLATION; TECHNOLOGY;

ACRYLAMIDES; ANIMALS; ANTIBODIES, MONOCLONAL; CHEMISTRY, PHARMACEUTICAL; DEXTRANS; GLYCOSYLATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNOGLOBULIN FRAGMENTS; POLYETHYLENE GLYCOLS; POLYMERS; RECOMBINANT PROTEINS; SIALIC ACIDS;

EID: 80052100915     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.602399     Document Type: Review

References (103)

1. Jain M, Kamal N, Batra SK. Engineering antibodies for clinical applications. Trends Biotechnol 2007;25:307-16 (Pubitemid 46899246)
2. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009;8:245-55.
3. Aggarwal S. Whats fueling the biotech engine-2009-10. Nat Biotechnol 2010;28:1165-71
4. Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33
5. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008;88:451-87 (Pubitemid 351522745)
6. Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105 (Pubitemid 27356788)
7. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60 (Pubitemid 37361705)
8. Duncan R. Polymer conjugates for drug targeting. From inspired to inspiration! J Drug Target 2006;14:333-5 (Pubitemid 44203513)
9. Kopecek JP, Kopeckova T, Minko ZR, et al. Water soluble polymers in tumor targeted delivery. J Control Release 2001;74:147-58
10. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113-28
11. Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010;49:6288-308.
12. Gaberc-Porekar V, Zore I, Podobnik B, et al. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 2008;11:242-50 (Pubitemid 351281064)
13. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-11 (Pubitemid 46986423)
14. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54:531-45 (Pubitemid 34615547)
15. Lee LS, Conover C, Shi M, et al. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem 1999;10:973-81.
16. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32
17. Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5:601-6 (Pubitemid 40593341)
18. Constantinou A, Chen C, Deonarain MP. Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol Lett 2010;32:609-22
19. Alzari PM, Lascombe MB, Poljak RJ. Three dimensional structure of antibodies. Annu Rev Immunol 1988;6:555-80
20. Constantinou A, Epenetos AA, Hreczuk-Hirst D, et al. Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconjug Chem 2008;19:643-50 (Pubitemid 351431395)
21. Constantinou A, Epenetos AA, Hreczuk-Hirst D, et al. Site-Specific Polysialylation of an Antitumor Single-Chain Fv Fragment. Bioconjug Chem 2009;20:924-31
22. Adams GP, Shaller CC, Chappell L, et al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000;27:339-46 (Pubitemid 30628692)
23. Popplewell AG, Tickle SP, Ladyman HM. Biological Products. Celltech Research and Development Ltd. US20070059307; 2007
24. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8 (Pubitemid 41483874)
25. Sasahara K. Temperature dependence of volume changes on glycine -PEG and L-alanaine-PEG in aqueous solution. Colloid Polym Sci 1995;273:782-6
26. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21 (Pubitemid 37361666)
27. Fee CJ, Van Alstine JM. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug Chem 2004;15:1304-13 (Pubitemid 39552020)
28. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83:601-6 (Pubitemid 24222392)
29. Yamaoka T, Tabata Y, Ikada Y. Fate of water-soluble polymers administered via different routes. J Pharm Sci 1995;84:349-54
30. Gursahani HJ, Riggs-Sauthier J, Pfeiffer D, et al. Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. J Pharm Sci 2009;98:2847-56
31. Cohen O, Kronman C, Chitlaru T, et al. Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. Biochem J 2001;357:795-802 (Pubitemid 32735159)
32. Yang K, Basu A, Wang M, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003;16:761-70 (Pubitemid 37442447)
33. Kitamura K, Takahashi T, Takashina K, et al. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun 1990;171:1387-94 (Pubitemid 20318105)
34. Kitamura K, Takahashi T, Yamaguchi T, et al. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res 1991;51:4310-15
35. Pedley RB, Boden JA, Boden R, et al. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994;70:1126-30 (Pubitemid 24358949)
36. Delgado C, Pedley RB, Herraez A, et al. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996;73:175-82
37. Chapman AP, Antoniw P, Spitali M, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999;17:780-3 (Pubitemid 29365106)
38. Yamasaki N, Matsuo A, Isobe H. Novel polyethylene glycol derivatives for modification of proteins. Agric Biol Chem 1988;52:2125-7
39. Koumenis IL, Shahrokh Z, Leong S, et al. Modulating pharmacokinetics of an anti-interleukin-8 F(ab)(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm 2000;198:83-95 (Pubitemid 30155552)
40. Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005;68:1439-54. (Pubitemid 41540000)
41. Mabry R, Rani M, Geiger R, et al. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 2005;73:8362-8 (Pubitemid 41740327)
42. Jayson GC, Parker GJ, Mullamitha S, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23:973-8
43. Trakas N. Tzartos, SJ. Conjugation of acetylcholine receptor-protecting Fab fragments with polyethylene glycol results in a prolonged half-life in the circulation and reduced immunogenicity. J Neuroimmunol 2001;120:42-9 (Pubitemid 33016723)
44. Leong SR, DeForge L, Presta L, et al. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine 2001;16:106-19 (Pubitemid 34081705)
45. Tsutsumi Y, Onda M, Nagata S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000;97:8548-53 (Pubitemid 30639710)
46. Kubetzko S, Balic E, Waibel R, et al. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006;281:35186-201 (Pubitemid 46043248)
47. Riley CJ, Engelhardt KP, Saldanha JW. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res 2009;69:1933-40
48. Monfardini C, Schiavon O, Caliceti O, et al. A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjug Chem 1995;6:62-9
49. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6 (Pubitemid 8116088)
50. Riley S. Business insights reports innovation in drug delivery. 2006
51. Fraser-Moodie I. Business insights reports. Delivery mechanisms for large molecule drugs. 2008
52. Wakefield IP, Burkly C, Garber L, et al. CDP7657, a monovalent Fab PEG anti-CD40L antibody, inhibits immune responses in both HuSCID mice and non-human primates. Arthritis Rheum 2010;62:1245
53. Ton NC, Parker GJ, Jackson A, et al. Phase I evaluation of CDP791, a PEGylated di-Fab conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 2007;13:7113-18 (Pubitemid 350276896)
54. Available from: http://www.ucb.com/ media-room/news-overview News archive [Accessed 5 June 11]
55. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005;5:111-24 (Pubitemid 40116484)
56. Tolcher AW, Sweeney CJ, Papadopoulos K, et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 2011;17:363-71
57. Harmsen MM, van Solt CB, Fijten HP, et al. Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol 2007;120:193-206 (Pubitemid 46216650)
58. Devy L, Rabbani SA, Stochl M, et al. PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia 2007;9:927-37 (Pubitemid 350086438)
59. Fleischmann R. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. Expert Opin Biol Ther 2010;10:773-86
60. Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348:36-41
61. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32 (Pubitemid 350206841)
62. Shaunak S, Godwin A, Choi JW, et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2006;2:312-13 (Pubitemid 43787211)
63. Available from: http://www.polytherics. co.uk/technologies/hipeg/ [Accessed 5 June 11]
64. Available from: http://www.polytherics. co.uk/technologies/cypeg/ [Accessed 5 June 11]
65. Available from: http://www.polytherics. co.uk/technologies/therapeg/ [Accessed 5 June 11]
66. Humphreys DP, Heywood SP, Henry A, et al. Alternative antibody Fab fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel 2007;20:227-34 (Pubitemid 351321304)
67. Gao W, Liu W, Christensen T, et al. In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc Natl Acad Sci USA 2010;107:16432-7
68. Gao W, Liu W, Mackay JA, et al. In situ growth of a stoichiometric PEG-like conjugate at a proteins N-terminus with significantly improved pharmacokinetics. Proc Natl Acad Sci USA 2009;106:15231-6
69. Available from:. http://www.ambrx.com/ wt/page/site-matters [Accessed 5 June 11]
70. Janas T, Janas T. Polysialic acid: structure and properties. Polysaccharides: structural diversity and functional versatility. CRC Publisher; 2004. p. 1224
71. Gregoriadis G, Jain S, Papaioannou I, et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm 2005;300:125-30 (Pubitemid 41112174)
72. Gregoriadis G, McCormack B, Wang Z, et al. Polysialic acids: potential in drug delivery. FEBS Lett 1993;315:271-6 (Pubitemid 23025022)
73. Fernandes AI, Gregoriadis G. Synthesis, characterization and properties of sialylated catalase. Biochim Biophys Acta 1996;1293:90-6 (Pubitemid 26089029)
74. Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm 2001;217:215-24. (Pubitemid 32268647)
75. Jain S, Hreczuk-Hirst D, McCormack B, et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta 2003;1622:42-9 (Pubitemid 36776349)
76. Available from: http://www.lipoxen.com/ pipeline/polyxen-product- pipeline.aspx [Accessed 5 June 11]
77. Stockert R. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995;75:591-609
78. Besheer A, Hause G, Kressler J, et al. Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. Biomacromolecules 2007;8:359-67 (Pubitemid 46323248)
79. Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009;23:93-109
80. Available from: http:/www.fresenius-kabi. com [Accessed 5 June 11]
81. Duncan R, Kopeckova P, Strohalm J, et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br J Cancer 1988;57:147-56 (Pubitemid 18085394)
82. Kopecek J, Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010;62:122-49
83. Seymour LW, Flanagan PA, al-Shamkhani A, et al. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Sel Cancer Ther 1991;7:59-73
84. Lu ZR, Kopeckova P, Kopecek J. Polymerizable Fab antibody fragments for targeting of anticancer drugs. Nat Biotechnol 1999;17:1101-4 (Pubitemid 29533550)
85. Fagnani R, Hagan MS, Bartholomew R. Reduction of immunogenicity by covalent modification of murine and rabbit immunoglobulins with oxidized dextrans of low molecular weight. Cancer Res 1990;50:3638-45 (Pubitemid 20194109)
86. Wileman TE, Foster RL, Elliott PN. Soluble asparaginase-dextran conjugates show increased circulatory persistence and lowered antigen reactivity. J Pharm Pharmacol 1986;38:264-71 (Pubitemid 16104212)
87. Fagnani R, Halpern S, Hagan M. Altered pharmacokinetic and tumour localization properties of Fab fragments of a murine monoclonal anti-CEA antibody by covalent modification with low molecular weight dextran. Nucl Med Commun 1995;16:362-9
88. Mikolajczyk SD, Meyer DL, Fagnani R, et al. Starling. Dextran modification of a Fab-beta-lactamase conjugate modulated by variable pretreatment of Fab with amine-blocking reagents. Bioconjug Chem 1996;7:150-8
89. Richter W, Kagedal L. Preparation of dextran-protein conjugates and studies of their immunogenicity. Int Arch Allergy Appl Immunol 1972;42:885-902
90. Kabat EA, Bezer AE. The effect of variation in molecular weight on the antigenicity of dextran in man. Arch Biochem Biophys 1958;78:306-18
91. Schlapschy M, Theobald I, Mack H, et al. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel 2007;20:273-84 (Pubitemid 47227182)
92. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879-83
93. Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 2009;27:1186-90 . Highlights the power and potential of extended hydrophilic peptides.
94. Available from:. http://www.amunix.com/ content/products/overview.htm [Accessed 5 June 11]
95. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997;15:26-32 (Pubitemid 27067150)
96. Wang M, Lee LS, Nepomich A, et al. Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Protein Eng 1998;11:1277-83 (Pubitemid 29012139)
97. Kogelberg H, Tolner B, Sharma SK, et al. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. Glycobiology 2007;17:36-45 (Pubitemid 44932814)
98. Stork R, Zettlitz KA, Muller D, et al. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008;283:7804-12
99. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-21 (Pubitemid 36397662)
100. Weenen C, Pena JE, Pollak SV, et al. Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. J Clin Endocrinol Metab 2004;89:5204-12 (Pubitemid 39391470)
101. Byrne B, Donohoe GG, OKennedy R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov Today 2007;12:319-26 (Pubitemid 46467485)
102. Constantinou A. Production and study of polysialylated antibodies for improved cancer therapy. PhD thesis, Imperial College London; 2005
103. Georgopoulou N, Breen KC. Overexpression of the alpha2,6 (N) sialyltransferase enzyme in human and rat neural cell lines is associated with increased expression of the polysialic acid epitope. J Neurosci Res 1999;58:641-51